Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

Lorraine Springuel, Tekla Hornakova, Elisabeth Losdyck, Fanny Lambert, Emilie Leroy, Stefan N. Constantinescu, Elisabetta Flex, Marco Tartaglia, Laurent Knoops, Jean Christophe Renauld

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The acquisition of growth signal self-sufficiency is 1 of the hallmarks of cancer. We previously reported that the murine interleukin-9-dependent TS1 cell line gives rise to growth factor-independent clones with constitutive activation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Here, we show that this transforming event results from activating mutations either in JAK1, JAK3, or in both kinases. Transient and stable expression of JAK1 and/or JAK3 mutants showed that each mutant induces STAT activation and that their coexpression further increases this activation. The proliferation of growth factor-independent TS1 clones can be efficiently blocked by JAK inhibitors such as ruxolitinib or CMP6 in short-term assays. However, resistant clones occur upon long-term culture in the presence of inhibitors. Surprisingly, resistance to CMP6 was not caused by the acquisition of secondary mutations in the adenosine triphosphate-binding pocket of the JAK mutant. Indeed, cells that originally showed a JAK1-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK3, whereas cells that originally showed a JAK3-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK1. These observations underline the cooperation between JAK1 and JAK3 mutants in T-cell transformation and represent a new mechanism of acquisition of resistance against JAK inhibitors.

Original languageEnglish
Pages (from-to)3924-3931
Number of pages8
JournalBlood
Volume124
Issue number26
DOIs
Publication statusPublished - Dec 18 2014

Fingerprint

Janus Kinases
Mutation
Chemical activation
Transcription
Transducers
Intercellular Signaling Peptides and Proteins
Clone Cells
Interleukin-9
T-cells
Assays
Phosphotransferases
Adenosine Triphosphate
Cells
Transcriptional Activation
T-Lymphocytes
Cell Line
Growth
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Springuel, L., Hornakova, T., Losdyck, E., Lambert, F., Leroy, E., Constantinescu, S. N., ... Renauld, J. C. (2014). Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood, 124(26), 3924-3931. https://doi.org/10.1182/blood-2014-05-576652

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. / Springuel, Lorraine; Hornakova, Tekla; Losdyck, Elisabeth; Lambert, Fanny; Leroy, Emilie; Constantinescu, Stefan N.; Flex, Elisabetta; Tartaglia, Marco; Knoops, Laurent; Renauld, Jean Christophe.

In: Blood, Vol. 124, No. 26, 18.12.2014, p. 3924-3931.

Research output: Contribution to journalArticle

Springuel, L, Hornakova, T, Losdyck, E, Lambert, F, Leroy, E, Constantinescu, SN, Flex, E, Tartaglia, M, Knoops, L & Renauld, JC 2014, 'Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors', Blood, vol. 124, no. 26, pp. 3924-3931. https://doi.org/10.1182/blood-2014-05-576652
Springuel L, Hornakova T, Losdyck E, Lambert F, Leroy E, Constantinescu SN et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014 Dec 18;124(26):3924-3931. https://doi.org/10.1182/blood-2014-05-576652
Springuel, Lorraine ; Hornakova, Tekla ; Losdyck, Elisabeth ; Lambert, Fanny ; Leroy, Emilie ; Constantinescu, Stefan N. ; Flex, Elisabetta ; Tartaglia, Marco ; Knoops, Laurent ; Renauld, Jean Christophe. / Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. In: Blood. 2014 ; Vol. 124, No. 26. pp. 3924-3931.
@article{443045c692c343509383bfa9efa9e85e,
title = "Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors",
abstract = "The acquisition of growth signal self-sufficiency is 1 of the hallmarks of cancer. We previously reported that the murine interleukin-9-dependent TS1 cell line gives rise to growth factor-independent clones with constitutive activation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Here, we show that this transforming event results from activating mutations either in JAK1, JAK3, or in both kinases. Transient and stable expression of JAK1 and/or JAK3 mutants showed that each mutant induces STAT activation and that their coexpression further increases this activation. The proliferation of growth factor-independent TS1 clones can be efficiently blocked by JAK inhibitors such as ruxolitinib or CMP6 in short-term assays. However, resistant clones occur upon long-term culture in the presence of inhibitors. Surprisingly, resistance to CMP6 was not caused by the acquisition of secondary mutations in the adenosine triphosphate-binding pocket of the JAK mutant. Indeed, cells that originally showed a JAK1-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK3, whereas cells that originally showed a JAK3-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK1. These observations underline the cooperation between JAK1 and JAK3 mutants in T-cell transformation and represent a new mechanism of acquisition of resistance against JAK inhibitors.",
author = "Lorraine Springuel and Tekla Hornakova and Elisabeth Losdyck and Fanny Lambert and Emilie Leroy and Constantinescu, {Stefan N.} and Elisabetta Flex and Marco Tartaglia and Laurent Knoops and Renauld, {Jean Christophe}",
year = "2014",
month = "12",
day = "18",
doi = "10.1182/blood-2014-05-576652",
language = "English",
volume = "124",
pages = "3924--3931",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

AU - Springuel, Lorraine

AU - Hornakova, Tekla

AU - Losdyck, Elisabeth

AU - Lambert, Fanny

AU - Leroy, Emilie

AU - Constantinescu, Stefan N.

AU - Flex, Elisabetta

AU - Tartaglia, Marco

AU - Knoops, Laurent

AU - Renauld, Jean Christophe

PY - 2014/12/18

Y1 - 2014/12/18

N2 - The acquisition of growth signal self-sufficiency is 1 of the hallmarks of cancer. We previously reported that the murine interleukin-9-dependent TS1 cell line gives rise to growth factor-independent clones with constitutive activation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Here, we show that this transforming event results from activating mutations either in JAK1, JAK3, or in both kinases. Transient and stable expression of JAK1 and/or JAK3 mutants showed that each mutant induces STAT activation and that their coexpression further increases this activation. The proliferation of growth factor-independent TS1 clones can be efficiently blocked by JAK inhibitors such as ruxolitinib or CMP6 in short-term assays. However, resistant clones occur upon long-term culture in the presence of inhibitors. Surprisingly, resistance to CMP6 was not caused by the acquisition of secondary mutations in the adenosine triphosphate-binding pocket of the JAK mutant. Indeed, cells that originally showed a JAK1-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK3, whereas cells that originally showed a JAK3-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK1. These observations underline the cooperation between JAK1 and JAK3 mutants in T-cell transformation and represent a new mechanism of acquisition of resistance against JAK inhibitors.

AB - The acquisition of growth signal self-sufficiency is 1 of the hallmarks of cancer. We previously reported that the murine interleukin-9-dependent TS1 cell line gives rise to growth factor-independent clones with constitutive activation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Here, we show that this transforming event results from activating mutations either in JAK1, JAK3, or in both kinases. Transient and stable expression of JAK1 and/or JAK3 mutants showed that each mutant induces STAT activation and that their coexpression further increases this activation. The proliferation of growth factor-independent TS1 clones can be efficiently blocked by JAK inhibitors such as ruxolitinib or CMP6 in short-term assays. However, resistant clones occur upon long-term culture in the presence of inhibitors. Surprisingly, resistance to CMP6 was not caused by the acquisition of secondary mutations in the adenosine triphosphate-binding pocket of the JAK mutant. Indeed, cells that originally showed a JAK1-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK3, whereas cells that originally showed a JAK3-activating mutation became resistant to inhibitors by acquiring another activating mutation in JAK1. These observations underline the cooperation between JAK1 and JAK3 mutants in T-cell transformation and represent a new mechanism of acquisition of resistance against JAK inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84919474961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919474961&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-05-576652

DO - 10.1182/blood-2014-05-576652

M3 - Article

VL - 124

SP - 3924

EP - 3931

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -